New Senolytic Drugs Force Cancer's Zombie Cells to Self-Destruct
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
20 articles
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
Plant compounds naturally target multiple cancer pathways simultaneously, offering advantages over pharmaceutical approaches.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within โ and blocking it may revive failed immunotherapies.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
Mouse study reveals the FXR bile acid receptor links gut microbes to arterial plaque in sleep apnea, hinting at new preventive targets.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
New compound AP503 activates GPR133 receptor to rebuild bone density in mice, offering hope for millions with osteoporosis.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months โ reshaping treatment strategy.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.